Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

ONC201 (Dordaviprone/TIC10) Variably Modulates Autophagy Response in HPV-Positive Cervical Cancer Cell Lines in a CLPP-Independent Manner.

Created on 13 Nov 2026

Authors

Sneha O Pathak, Ishaan Shah, Tanishka Khedekar, Sonal M Manohar

Published in

Journal of biochemical and molecular toxicology. Volume 40. Issue 11.

Abstract

ONC201, also known as dordaviprone or TIC10, a first-in-class member of the imipridone family, has recently received fast-track FDA approval for recurrent diffuse midline glioma. It has shown therapeutic promise and a suitable safety profile in both solid and hematologic malignancies. We recently reported in vitro efficacy of ONC201 in cervical cancer cell lines despite its differential effects on its targets viz. caseinolytic protease (CLPP), TRAIL and DR5 in each of these cell lines. In the current study, we show that ONC201 treatment leads to distinct phenotypic outcomes i.e. significant apoptosis in HeLa cells vs. autophagy in SiHa cells. We further show opposing outcomes upon inhibition of autophagy in both of these cell lines i.e. enhanced apoptosis-inducing potential of ONC201 against SiHa cells and restrained apoptotic response in the case of HeLa cells. Knockdown studies using siRNA suggest that the autophagy modulation by ONC201 in HeLa cells is independent of its well-known target CLPP which is widely reported to play a role in cytoprotective autophagy. This is the first report on the ability of ONC201 to modulate the autophagy pathway in cancer cells.

PMID:
43023413
Bibliographic data and abstract were imported from PubMed on 13 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 7
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement